Growth suppression of human oral cancer cells by candidate agents for cetuximab-side effects-Reference-Cited by-同舟云学术

Growth suppression of human oral cancer cells by candidate agents for cetuximab-side effects

Published:2019-03 Issue:2 Volume:376 Page:210-220
ISSN:0014-4827
Container-title:Experimental Cell Research
language:en
Short-container-title:Experimental Cell Research

Author:

Uzawa Katsuhiro,Kasamatsu Atsushi,Saito Tomoaki,Kita Akihiro,Sawai Yuki,Toeda Yuriko,Koike Kazuyuki,Nakashima Dai,Endo Yosuke,Shiiba Masashi,Takiguchi Yuichi,Tanzawa Hideki

Funder

Grant-in-Aid for Challenging Exploratory Research

Publisher

Elsevier BV

Subject

Cell Biology

Reference50 articles.

1. Global cancer statistics, 2012;Torre;Cancer Stat. CA Cancer J. Clin.,2015

2. Epidemiology of oral cancer in Asia in the past decade – an update (2000–2012);Rao;Asian Pac. J. Cancer Prev.,2013

3. Squamous cell carcinoma of the oral cavity: clinical and pathological aspects;Fronie;Rom. J. Morphol. Embryol.,2013

4. EGFR protein overexpression and gene copy number increases in oral tongue squamous cell carcinoma;Ryott;Eur. J. Cancer,2009

5. A randomized, phase 2 study of cetuximab plus cisplatin with or without paclitaxel for the first-line treatment of patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck;Bossi;Ann. Oncol.,2017

Cited by 6 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. MAPK Signaling Pathway in Oral Squamous Cell Carcinoma: Biological Function and Targeted Therapy;Cancers;2022-09-23

2. HCRP‑1 alleviates the malignant phenotype and angiogenesis of oral squamous cell carcinoma cells via the downregulation of the EGFR/STAT3 signaling pathway;Oncology Letters;2022-09-16

3. The Flavagline Compound 1-(2-(dimethylamino)acetyl)-Rocaglaol Induces Apoptosis in K562 Cells by Regulating the PI3K/Akt/mTOR, JAK2/STAT3, and MAPK Pathways;Drug Design, Development and Therapy;2022-08

4. Therapeutic applications of herbal/synthetic/bio-drug in oral cancer: An update;European Journal of Pharmacology;2021-01

5. Chemotherapy Toxicities;Oncologic Emergency Medicine;2021